The invention provides a process for the standardization of subcutaneous allergen immunotherapy formulas resulting in increasing availability and decreasing costs, allowing for expanded and improved relief for a greater number of allergy sufferers.This invention provides a lower cost treatment to increase availability of the benefits of subcutaneous immunotherapy via standardization of most common seasonal or year round allergens for treatment. Standardizing a formula containing multiple allergen types allows a large population of potential users to benefit from a wide spectrum of included allergen sensitivities. Mass production of non-customized formulas allows for cost reduction, which breaks down a major barrier to current demand. The availability of non-individualized reduced allergen extract concentration strength formula allows for cost-effective availability in less-specialized delivery channels, which breaks down the other major barrier to current demand.
